August 10, 2020
Via: medicaldevice-network.comThe US Food and Drug Administration (FDA) has approved Guardant Health’s Guardant360 CDx for tumour mutation profiling in patients with any solid malignant neoplasm (cancerous tumour). The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell […]
January 31, 2023
January 26, 2023
Copyright © 2023. All rights reserved
